title: Organizational and Management Impact Analysis of Using the New Subcutaneous Formulation of Tocilizumab in Selected Italian Rheumatology Centers.
authors.affiliation: Roche S. p. A., Monza, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Ravera
authors.affiliation: Roche S. p. A., Monza, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Tomic
authors.affiliation: University of Verona, Verona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.affiliation: University of Verona, Verona, Italy.
authors.forename: O
authors.initials: O
authors.lastname: Viapiana
authors.affiliation: Roche S. p. A., Monza, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Paolini
authors.affiliation: Roche S. p. A., Monza, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Bianchino
authors.affiliation: Emmeffe S. r. l., Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Canciani
authors.affiliation: Emmeffe S. r. l., Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Farina
authors.affiliation: Ferrara University, Ferrara, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ciancio
authors.affiliation: Ferrara University, Ferrara, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Govoni